Review · PMID 41004910
Bioactive Peptides and Proteins in Neurodegenerative Diseases: Neuroprotective Roles — VialBase Research
Semax identified among key neuroprotective peptides (alongside NGF, BDNF, GDNF, Exendin-4)
Last updated · 2025 · Various · Neuropeptides
Key findings
- Semax identified among key neuroprotective peptides (alongside NGF, BDNF, GDNF, Exendin-4)
- Multifunctional action: reduces oxidative stress, inhibits neuroinflammation, preserves mitochondria, enhances synaptic plasticity
- Demonstrates efficacy in preclinical and early clinical studies for AD, PD, HD
- Peptide-based therapeutics offer multi-target approach vs single-target drugs
Semax in Neuroprotective Peptide Landscape (PMID: 41004910)
Review Scope
- Comprehensive review of bioactive peptides for neurodegenerative diseases
- Covers Alzheimer’s, Parkinson’s, Huntington’s, and others
- Positions Semax alongside growth factors (NGF, BDNF, GDNF) and Exendin-4
Key Points on Semax
- Reduces oxidative stress in CNS tissue
- Inhibits neuroinflammation via cytokine modulation
- Preserves mitochondrial function
- Enhances synaptic plasticity (BDNF pathway)
- Multifunctional profile = advantage over single-target drugs
Relevance
Validates Semax as a legitimate neuroprotective agent in the broader peptide therapeutics landscape. Its multi-target mechanism makes it potentially superior to single-target neuroprotective drugs that have largely failed in clinical trials for NDD.